Compare
ProtoKinetix, Inc. vs Bioxytran, Inc vs ZyVersa Therapeutics, Inc. vs Provectus Biopharmaceuticals, Inc.
| Latest fiscal year | ProtoKinetix, Inc. PKTX | Bioxytran, Inc BIXT | ZyVersa Therapeutics, Inc. ZVSA | Provectus Biopharmaceuticals, Inc. PVCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $336.1K |
| Revenue growth (YoY) | n/a | n/a | n/a | -45.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$393.6K | -$2.12M | -$24.95M | -$5.43M |
| EPS (Diluted) | $0.00 | -$0.02 | -$4.18 | -$0.01 |
| Operating cash flow | -$135.4K | -$526.5K | -$5.11M | -$3.33M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | n/a | n/a | $251.3K |
| Total assets | $483.4K | $658.6K | $347.9K | $697.5K |
| Total liabilities | n/a | $3.25M | $12.73M | $7.00M |
| Shareholders' equity | $297.9K | -$2.59M | -$12.39M | -$6.30M |
| Return on year-end equity | -132.1% | n/a | n/a | n/a |
| Shares outstanding | 406.83M | 108.15M | 8.10M | 420.28M |
Revenue, most recent five fiscal years
| Fiscal year | ProtoKinetix, Inc. | Bioxytran, Inc | ZyVersa Therapeutics, Inc. | Provectus Biopharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2014-12-31 | $191.1K Ended 2017-12-31 | n/a | $336.1K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2013-12-31 | $246.5K Ended 2016-12-31 | n/a | $617.1K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2012-12-31 | $255.8K Ended 2015-12-31 | n/a | $557.7K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2011-12-31 | $275.6K Ended 2014-12-31 | n/a | $989.0K Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2010-12-31 | $417.3K Ended 2013-12-31 | n/a | n/a |